Videos

IMPACT-PLuS follow-up data show 35% of children treated with peanut OIT had a reaction years later, with 5 requiring epinephrine, Jennifer Dantzer, MD, says.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.

IMPACT-PLuS follow-up found 80% of children treated with early-life peanut oral immunotherapy remained peanut tolerant 8 to 11 years later.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how informal mentorship moments improve training and care for skin of color.

One year after FDA approval, Basavaraj discusses NTM overlap, geographic variation, and real-world access in bronchiectasis care.

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how mentorship shapes dermatology careers and supplements trainee education.

Carotid ultrasound data reveal early arterial injury even at earlier CKM stages, says Donald Lloyd-Jones, MD, MS

Manish Wadhwa, MD, discusses Implicity’s newest algorithm to improve the accuracy of implantable cardiac monitors in identifying arrhythmic episodes.

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Genetic variants tied to CAR T toxicity and expansion could guide how researchers screen healthy donors for allogeneic CAR T products.

Lp(a) is one of the biggest contributors to cardiovascular disease, but recent studies have shown that awareness of and testing for the condition is subpar nationwide.

In this interview, Melinda Gooderham, MD, MSc, touches on eyebrow and eyelash regrowth data and safety findings for upadacitinib in severe alopecia areata.

Melinda Gooderham, MD, MSc, discusses new JAMA data on upadacitinib's efficacy for severe alopecia areata in adults and adolescents.

Remick discusses multidisciplinary teams, adherence issues, and the path forward for heart failure care in this post-forum interview.

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

Robert Sarkany, MD, FRCP, discusses PORT-77's phase 2a safety profile in EPP and the endpoints to watch as the drug advances to phase 2b/3.

Investigators outline how phase 1 safety data could inform a phase 2 efficacy study and eventual pediatric enrollment down to age 4 years.

In this interview, Robert Sarkany, MD, FRCP, explains the biology behind erythropoietic protoporphyria and how PORT-77 targets its underlying cause.

The first-in-human study is testing an ascending-dose microneedle device designed to deliver peanut protein through the skin in just 3 minutes.

Philippe Généreux, MD, discusses a secondary analysis of EARLY TAVR examining patients excluded from the trial for positive treadmill stress tests.

Tiffany Mayo, MD, reflects on the pressure of visibility in medical leadership and why boundary-setting becomes essential.

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Thomas Pieber, MD, discusses a recent phase 1 trial investigating AT278’s efficacy in patients with T2D and obesity compared to other fast-acting insulins.

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how mentorship shapes dermatology careers and improves care for skin of color.

Raj Chovatiya, MD, PhD, discusses why bimekizumab response durability in HS held steady regardless of disease duration, and what it means for care.